Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Welcome to Outlook 2019.

A New Year and a new look. For 2019 we have merged the Scrip 100 publication with In Vivo’s yearly annual preview magazine, creating a new beast known as Outlook. This encompasses all the best aspects of both issues and covers more topic areas than ever before.

Outlook 2019 includes annual league tables for both the top 100 biopharmaceutical and top 100 medical technology companies, ranking the leaders of each sector by their 2017 full-year financial performance. A full analysis of the biopharmaceutical and medtech sectors’ financial data is included in our headline chapter – Scrip 100. Here you will also find interactive datasets that allow you to sort and compare companies as you like.

Monetary scrutiny is not the only reason to investigate the content of Outlook 2019. Bringing in something new, the Outlook chapter includes detailed forward-looking articles that focus on the state of play for the biopharma and medtech industries in the coming year. Written by In Vivo’s executive editors William Looney and Ashley Yeo, the Outlook section covers a lot of ground to help industry execsget up to speed with the biggest changes, challenges and trends that are expected to disrupt the life sciences sector over the next 12 months.

Outlook 2019 has all the favorites from the previous Scrip 100 issue, including chapters on business, leadership, R&D, clinical trials and regulation. But this year, our special edition also includes sections on medtech, generics and biosimilars, plus gene therapy.

Highlights inside these chapters include: an exclusive interview with Scrip’s Lifetime Achievement Award winner for 2018, Professor Sir John Bell; a closer look at the complex biosimilar market in Asia; interviews with C-suite members from Regeneron, Novartis, AstraZeneca, GE Healthcare, Philips, BC Platforms and more; insights from the head of the Danish Medicines Agency, Thomas Senderovitz; a review of pharma’s M&A activity in 2018 and expectations for the year ahead; and articles exploring the complex arena of cell and gene manufacturing and logistics.

Included in the online Outlook offering is our Legacy chapter that includes PDFs of Scrip 100 since 2009 and copies of In Vivo’s former Outlook issues. The online selection also includes interactive exhibits throughout various chapters and downloadable infographics.

Lucie Ellis

Managing Editor, In Vivo & Outlook